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Abstract
Purpose The pathophysiological underlying mechanism of
spontaneous HBsAg clearance in hepatitis B virus (HBV)
infected patients is largely unknown. However, serum
hyaluronic acid (sHA) plays a role in liver fibrosis progression
and reversely could serve as a potential biomarker for HBsAg
clearance. This study investigates whether low sHA is associ-
ated with HBsAg loss in non-Asian HBV patients.
Methods Non-Asian women living in Amsterdam with
known chronic HBV infection between 1990–2003 were in-
vited for a single follow-up visit at the Municipal Health
Service Amsterdam between September 2011 to May 2012.
Serum hyaluronic acid and liver stiffness measurement togeth-
er with clinical evaluation, biochemical and virologic blood
tests were performed.
Results Of the 160 women, HBsAg loss occurred in 38 (23%)
patients between diagnosis and follow-up. sHA levels were
lower in HBsAg negative patients compared to HBsAg posi-
tive patients (14.5 [9.4–27.2] ng/mL vs 25.0 [12.3–42.5] ng/
mL, p <0.01). A similar distinction in sHA between low and
high HBV DNA was noted. sHA had a significant discrimi-
natory ability to differentiate between HBsAg positive and
HBsAg negative patients, (AUC 0.65 [95 % CI 0.55–0.75],
p<0.01). In multivariable analysis only sHA level was asso-
ciated with HBsAg loss (OR 0.4 [0.2–0.9]). Finally, F3-F4
fibrosis (cut-off >8.1 kPa) was diagnosed in 3 % in HBsAg
negative patients compared to 10 % in HBsAg positive pa-
tients (p=0.15).
Conclusion Serum HA levels are lower in patients who expe-
rience spontaneous HBsAg loss compared to HBsAg positive
patients.
Introduction
Liver inflammation is the hallmark of hepatotropic viruses
like hepatitis B virus (HBV). During this chronic hepatic in-
flammation, synthesis and turnover of the extracellular matrix
(ECM) is modulated by several cytokines with serum
hyaluronic acid (sHA) being one of its major ECM compo-
nents [1, 2]. In healthy persons, sHA levels vary between 23
and 129 ng/mL [3, 4]. sHA levels have already been shown to
be higher in patients with chronic hepatitis C or active auto-
immune hepatitis than those of healthy individuals without
signs of hepatitis [5–7]. In addition, in chronic HBeAg nega-
tive HBV patients, high serum sHA positively correlates with
fibrosis progression and level of inflammation [8]. Based on
these observations, sHA level might be a reflection of the
intensity of the immune response in chronic liver diseases.
Annually, approximately 2 % of all chronic hepatitis B
virus (HBV) infected patients experience HBV surface anti-
gen (HBsAg) loss without antiviral therapy (i.e. spontaneous
HBsAg clearance) [9]. Although the exact pathophysiological
mechanism of spontaneous HBsAg loss in patients with
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chronic HBV has not been fully understood, there is some
evidence that a T-cell mediated immune response may be es-
sential in this process [10]. Rehermann et al. [11] demonstrat-
ed that chronic HBV patients who cleared HBsAg, spontane-
ously or after interferon-alfa treatment, had a strong HBV
multispecific cytotoxic T-lymphocyte response that was sim-
ilar to those clearing HBsAg after an acute infection. Several
histological studies have shown that after spontaneous HBsAg
loss, liver inflammation declined over time [12, 13].However,
it is unknown whether sHA levels also decline after spontane-
ous HBsAg loss and if sHA could serve as a potential bio-
marker for HBsAg clearance. The aim of this study was to
investigate whether a low sHA level is associated with HBsAg
loss in patients with chronic HBV.
Materials and methods
Patient selection
The study population has already been described previously
[14]. Briefly, non-Asian women in the greater Amsterdam
area, who were registered as chronic HBV patients between
1990 and 2004, were invited for a single study visit between
September 2011 and May 2012 at the Municipal Health
Service of Amsterdam. History taking and physical examina-
tion were performed, along with a liver stiffness measurement
(LSM) and blood tests to determine the hyaluronic acid level
and biochemical and virological tests. The following bio-
chemical tests were determined: bilirubin, alanine aminotrans-
ferase (ALT), aspartate aminotransferase (AST), Gamma-
glutamyl transpeptidase (GGT), alkaline phosphatase (ALP)
and albumin. For this study 14 patients were excluded from
the 174 included patients (three with HCV co-infection, five
with previous HBV treatment, one with acute HBV infection
and five due to indeterminate sHA which was a result of not
enough serum to determine the sHA), resulting in a study
population of 160 participants.
Spontaneous HBsAg loss was defined as having a positive
HBsAg antigen in the historic sample with subsequent HBsAg
negativity during the follow-up visit without previously being
subjected to antiviral therapy. The study protocol was approved
by the Ethical Committee of the Academic Medical Center
Amsterdam. Written approval was obtained from the Public
Health Service Amsterdam. Informed consent was obtained
from each participant (clinical trials number NCT01462981).
Laboratory tests
Hyaluronic acid levels were measured in serum at the follow-
up visit as part of the ELF-test by the ADVIA Centaur XP
(Siemens, Erlangen, Germany). This assay has a lower detec-
tion limit of 1.6 ng/ml, a linear range from 1.6 to 1000 ng/ml,
and higher concentrations are expressed as >1000 ng/ml.
Linearity, sensitivity and precision were evaluated according
to CLSI guidelines. HBV DNA was determined with the
COBAS Ampliprep/COBAS Taqman assay, v.2.0 (Roche
Molecular Diagnostics, California, USA) with a lower detec-
tion limit of 20 IU/ml. Qualitative anti-HCV, anti-HIV and
qualitative HBsAg were also performed with the ADVIA
Centaur XP assay. Lastly, liver-related biochemical parame-
ters were determined according to local standard laboratory
procedures. HBV DNA levels were divided in more or less
than 2000 IU/mL that was derived from current international
guidelines [15, 16].
Liver stiffness measurement
An experienced researcher (S.H.) performed the LSM with a
Fibroscan® (model F402 Echosens, France) according to stan-
dard operating procedures supplied by the manufacturer and
as described by others [17]. The METAVIR classification was
used to determine the fibrosis stage, categorizing no to mild
fibrosis (F0/F2) with a score less than or equal to 8.1 kPa and
severe fibrosis to cirrhosis (F3/F4) with a score above 8.1 kPa
based on a cut-off value from previous studies in chronic HBV
patients [18, 19].
Statistical analysis
Continuous variables were expressed as a median with inter-
quartile range (IQR) and categorical variables as frequencies
with percentage. Differences between HBsAg positive and
HBsAg negative groups were calculated with the Mann–
Whitney U test (continuous variables) or chi-square test (cat-
egorical variables). Factors associated with HBsAg loss were
analysed with univariable and multivariable logistic regres-
sion. Factors with a p-value<0.10 in univariable analysis were
included in the multivariable logistic regression. Correlation
between ALT levels and sHA levels were calculated with the
Spearman rho correlation. A receiver-operator characteristic
(ROC) curve was constructed to assess the value of sHA in
discriminating HBsAg positive patients fromHBsAg negative
patients and to determine an optimal cut-off value for the sHA.
A ROC curve with an area under curve (AUC) less than 0.60
and a p-value >0.05 was considered unreliable for the ROC
curve. Outcomes were reported as odds ratio (OR) with 95 %
confidence intervals (CI), and a p-value <0.05 was considered
significant. The statistical analysis was performed with SPSS
v17 (version 17.0; SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics are given in Table 1. At the time of the
follow-up study visit, HBsAg loss was documented in 38
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(23 %) patients resulting in 122 HBsAg positive patients, all
being HBeAg negative. All HBsAg negative patients had an
undetectable HBV DNA level (i.e. <20 IU/ml). Of the 117
patients with a liver stiffness result, occurrence of F3-F4 fi-
brosis was lower in the HBsAg negative patients compared to
HBsAg positive patients (one in 38 HBsAg negative patients
(3 %) vs 12 in 122 HBsAg positive patients (10 %), p=0.15).
Hyaluronic acid level and HBV parameters
To explore whether sHA levels were different between
HBsAg positive and HBsAg negative patients, sHA levels
were compared in both groups. The median (IQR) sHA level
of all included patients was 21.9 (11.7–41.2) ng/mL. HBsAg
negative patients had a significantly lower sHA level com-
pared to HBsAg positive patients (14.5 [9.4–27.2] ng/mL vs
25.0 [12.3–42.5] ng/mL, p <0.01) (Fig. 1). In addition, when
patients were categorized into low HBV DNA level (HBV
DNA less than or equal to 2000 IU/mL) and high HBV
DNA level (HBV DNA>2000 IU/mL), there was a trend to-
wards lower sHA levels in the low HBV DNA patients com-
pared to the patients with high HBV DNA (20.6 [11.2–40.4]
ng/mL vs 26.3 [14.7–44.4] ng/mL, p=0.07).
Overall, there was a positive correlation between sHA
levels and ALT level in the whole study population (r=0.20,
p=0.01) (data not shown). However, when patients were
divided by HBsAg status, this correlation was lost (HBsAg
positive group r=0.16, p=0.08 and HBsAg negative group,
r=0.11, p=0.49). The sHA had a significant diagnostic dis-
criminatory power to detect HBsAg negative patients (AUC
0.65 [95 % CI 0.55–0.75], p<0.01). A cut-off value of
16.9 ng/mL was selected to have the optimum in both sensi-
tivity and specificity. Subsequently, patients were divided in
two groups, either low or high sHA. There were 68 (43 %)
patients with a low sHA level compared to 92 (57 %) patients
with a high sHA level. Of the 38 HBsAg negative patients, 25
(66 %) had a low sHA level (i.e. below 16.9 ng/mL) and 13
(34 %) a high sHA level.
Factors associated with HBsAg loss
Next, we performed univariable and multivariable analyses to
identify factors that were associated with HBsAg loss. The
results are shown in Table 2. In univariable analysis, which
included age, BMI, ethnic origin, smoking, alcohol consump-
tion, ALT level, AST level, sHA level, HBV DNA and fibro-
sis stage as factors, alcohol consumption [OR 0.3 (0.1–0.9)]
and a high sHA level [OR 0.3 (0.1–0.6)] were associated with
increased chance to loose HBsAg. BMI, smoking, and ALT
level had a close, but statistically not significant association
with HBsAg loss [BMI OR 0.5 (0.2–1.1), smoking OR 0.3
(0.1–1.0) and ALT OR 0.5 (0.2–1.0)]. When all significant or
Table 1 Characteristics of the study population by HBsAg status
Characteristic HBsAg positive patients (N =122) HBsAg negative patients (N=38) p-value
Age, years median (IQR) 45 (41–49) 44 (39–48) 0.57
Follow-up, years median (IQR) 18 (13–20) 18 (14–20) 0.85
BMI, kg/m² median (IQR) 30 (27–33) 29 (25–34) 0.85
Alcohol, n (%)a 39 (31) 5 (13) 0.02
Smoking, n (%)b 28 (23) 3 (8) 0.03
Origin, n (%) 0.04
Turkey 33 (27) 19 (50)
Ghana 31 (25) 3 (8)
Surinam 25 (21) 5 (13)
Morocco 24 (20) 7 (18)
Other 9 (7) 4 (11)
ALT, U/L median (IQR) 18 (15–26) 16 (12–21) 0.11
AST, U/L median (IQR) 17 (13–23) 15 (12–19) 0.16
Trombocytes, 109/L median (IQR) 249 (201–287) 245 (218–284) 0.94
Protrombin time, seconds median (IQR) 13.1 (12.8–13.5) 13.2 (12.6–13.5) 0.82
Log HBV DNA, IU/mL median (IQR) 2.7 (1.9–3.5) n/a n/a
F3-F4 fibrosis, n (%)c 12 (10) 1 (3) 0.15
BMI body mass index, ALT alanine aminotransferase, AST aspartate aminotransferase, IQR interquartile range, U/L units per liter, IU/mL international
units per milliliter, n/a not applicable
a Alcohol consumption defined as more than one glass per week
b Smoking defined as more than one cigarette per week
c Determined by liver stiffness measurement
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borderline significant factors from univariable analysis were
included in a multivariable analysis, only those patients with a
high sHA level had a lower chance to lose HBsAg (OR 0.4
[0.2–0.8]).
Discussion
Spontaneous HBsAg loss in chronic HBV-infected patients is
a phenomenon that is still not well understood. This study
clearly shows that chronically HBV infected patients who lost
HBsAg had lower sHA levels compared to patients who
remained positive.
Though not reported in the literature previously, there are
several arguments to explain this finding. First, sHA is a li-
gand of CD44 that is expressed in numerous cells, including
liver sinus endothelial cells, neutrophils and regulatory T-cells
(Tregs) [20, 21]. Data from experimental studies in other dis-
eases have shown that there is an interplay between sHA and
the immune system during chronic inflammation. On the one
hand, studies in lung fibroblasts have shown that cytokines
such as TNF-a activate the production of sHA [22].
Subsequent sHA-CD44 binding then promotes T-cell adhe-
sion and migration to the endothelium to engage in an inflam-
matory process. On the other hand, there is also evidence that
sHA stimulates the anti-inflammatory pathway of the immune
system [23]. In an in vitro study, sHA binding to CD44 was
correlated with a high suppressive activity of Tregs [23].
Second, in chronic HBV-infected patients experiencing
spontaneous HBsAg loss, early studies have shown that the
inflammatory process in the liver declined after HBsAg clear-
ance [12, 13]. Although the interplay between sHA, inflam-
mation and HBsAg loss has to be further elucidated, we hy-
pothesize that HBsAg loss dampens the immune system
which in turn suppresses the synthesis of sHA leading to
low sHA levels.
Several studies have investigated the value of sHA (or sHA
as a component of the enhanced liver fibrosis [ELF] test) in
patients with chronic HBV [8, 24–31]. However, these studies
differ in several aspects from our study. First, until now studies
in HBV patients have only focused on the role of sHA in the
identification of liver fibrosis. Second, the study population of
previous studies differed from our study, since previous stud-
ies either included only HBsAg positive patients or did not
separate patients based on their HBsAg status (when HBsAg
status of the included patients was not mentioned). Third, the
cut-off value of the sHA concentration in our study is much
lower than the cut-off values of other studies which varied
between 52 and 300 ng/mL [25, 27]. Since we have shown
that lower sHA values than previously reported are necessary
Fig. 1 Distribution of serum
hyaluronic acid according to
HBsAg status (a), HBV DNA
level (b) and fibrosis stage (c).
LSMliver stiffness measurement
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to differentiate between patients with and without spontane-
ous HBsAg loss, this association could have gone unnoticed
by others.
Since this was a cross-sectional study, we could not explore
whether the sHA levels could be of predictive value to identify
future candidates for spontaneous HBsAg loss. A prospective
longitudinal study with multiple time points in which sHA
levels would be determined and in which the moment of
HBsAg loss is documented is needed to clarify this question.
This would also allow for exploration of additional variables,
which could be fitted into an algorithm, to identify chronic
HBV patients who will experience spontaneous HBsAg loss
in an early stage to avoid unnecessary antiviral therapy. The
advantage of sHA is that it is easily accessible and available,
relatively inexpensive and a small amount of serum is required
for the assay.
In conclusion, serum HA levels are significantly lower in
chronic HBeAg negative HBV patients who experience spon-
taneous HBsAg loss in comparison to those still being HBsAg
positive. Further validation studies are needed to determine
Table 2 Analysis of factors associated with spontaneous HBsAg loss
Factor Total (N) HBsAg negative
cases (%)
Univariable analysis
OR (95 % CI)
p-value Multivariable analysis
OR (95 % CI)
p-value
Age
≤ 45 years 85 22 (26) 1 (reference) 0.50 1 (reference)
> 45 years 75 16 (21) 0.8 (0.4–1.6)
BMI
≤ 25 kg/m² 24 9 (38) 1 (reference) 0.09 1 (reference) 0.10
> 25 kg/m² 136 29 (21) 0.5 (0.2–1.1) 0.4 (0.2–1.2)
Ethnic origin
Turkey 52 19 (37) 1 (reference) 0.18 1 (reference)
Ghana 34 3 (9) 1.3 (0.4–4.9)
Surinam 30 5 (17) 0.2 (0.1–1.2)
Morocco 31 7 (23) 0.5 (0.1–2.1)
Other origin 108 19 (18) 0.7 (0.2–2.8)
Smokinga
No 129 35 (27) 1 (reference) 0.05 1 (reference) 0.06
Yes 31 3 (10) 0.3 (0.1–1.0) 0.3 (0.1–1.1)
Alcohol consumptionb
No 116 33 (28) 1 (reference) 0.03 1 (reference) 0.17
Yes 44 5 (11) 0.3 (0.1–0.9) 0.5 (0.2–1.4)
ALT
≤ 0.5 x ULN 88 26 (30) 1 (reference) 0.06 1 (reference) 0.26
> 0.5 x ULN 72 12 (17) 0.5 (0.2–1.0) 0.6 (0.3–1.4)
AST
≤ 0.5 x ULN 150 38 (25) 1 (reference) 1 (reference)
> 0.5 x ULN 10 0 (0) n/a
HA level
Low 68 25 (37) 1 (reference) <0.01 1 (reference) 0.01
High 92 13 (14) 0.3 (0.1–0.6) 0.4 (0.2–0.8)
HBV DNA level
Low/undetectable 118 38 (32) 1 (reference) 1 (reference)
High 42 0 (0) n/a
Fibrosis stage
F3-F4 13 1 (8) 1 (reference) 0.17 1 (reference)
F0-F2 105 23 (22) 5.8 (0.7–49.1)
Indeterminate 42 14 (33) 3.4 (0.4–27.6)
BMI body mass index, ALT alanine aminotransferase, AST aspartate aminotransferase, ULN upper limit of normal, OR odds ratio, 95% CI 95 percent
confidence interval, n/a not applicable
a Smoking defined as more than one cigarette per week
b Alcohol consumption defined as more than one glass per week
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the predictive value of sHA with potential other variables in
the natural history of chronic HBV.
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